- Dayang Chem (Hangzhou) Co., Ltd.
- China
- Product Name: GLUCAGON (1-37) (PORCINE)
- Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
- Purity: 98.0%
- Stocking Period: Inquiry
- Contact: Ms Wang
- Zhejiang Hangyu API Co., Ltd
- China
- Product Name: Oxyntomodulin (bovine, dog, porcine)
- Price: $Inquiry/1kg
- Purity: 99.0%
- Stocking Period: 1 Day
- Contact: Vinnie
74870-06-7
74870-06-7 structure
- Name: Oxyntomodulin (bovine, dog, porcine) trifluoroacetate salt
- Chemical Name: GLUCAGON (1-37) (PORCINE)
- CAS Number: 74870-06-7
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Metabolic Disease
- Create Date: 2018-07-17 10:33:35
- Modify Date: 2024-02-08 16:00:30
-
Oxyntomodulin (swine) is a dual agonist for GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), a peptide hormone released from the gut in post-prandial state. Oxyntomodulin (swine) suppresses appetite and reduces food intake[1][2][3].
| Name | GLUCAGON (1-37) (PORCINE) |
|---|
| Description | Oxyntomodulin (swine) is a dual agonist for GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), a peptide hormone released from the gut in post-prandial state. Oxyntomodulin (swine) suppresses appetite and reduces food intake[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Oxyntomodulin (0-1000 nM; 24 or 48 h) promotes neural cell proliferation in a dose- and time-dependent manner[3]. Oxyntomodulin (0-1000 nM; 24 h) protects against glutamate toxicity and oxidative stress in neuronal cells[3]. Oxyntomodulin (100 nM; 24 h) reduces glutamate-mediated neurotoxicity in primary cortical neurons in a dose-dependent manner[3]. Cell Proliferation Assay[3] Cell Line: SH-SY5Y and SH-hGLP-1R #9 cells Concentration: 0, 1, 10, 100, 1000 nM Incubation Time: 24 or 48 h Result: Increased cell viabilities at 24 h after treatment in hGLP-1R overexpressing #9 cells. Enhanced cell viability in both SH-SY5Y and #9 cells at 48 h after treatment. |
| In Vivo | Oxyntomodulin (intracerebroventricular administration; 20 μg per rat; once) treatment improves locomotor activity in stroke rats, and reduces cerebral infarction[3]. Animal Model: Transient middle cerebral artery occlusion (MCAo) rat model[3] Dosage: 20 μg per rat Administration: Intracerebroventricular administration; 20 μg per rat; once Result: Increased horizontal activity, movement number, movement time, total distance travelled, vertical activity, vertical movement number, and vertical movement time, compared to vehicle control group. Reduced the extent of cortical infarction compared to vehicle control group. |
| Storage condition | -15°C |
|---|